Scenic Biotech Enters Cooperative Research & Development Agreement wit...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: March 26, 2023

Statement from the Chief Public Health Officer of Canada on World TB Day • SBNY LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Signature Bank Investors to Secure Counsel Before Important D • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t • DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio • National University Receives 2023 Military Friendly® Gold Designation • Korelya Capital Invests in Weo, Bringing Total Funds Raised to $15M, and Leads Launch of its Series A Financing Round • GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office • Otr Elkalam: All the Way from Hollywood to Riyadh An American Contestant Travels to Participate in the Largest Religious Competi • HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers • Philadelphia Works Names First Female Chief Operating Officer • SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los • Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates • ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting • NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Aga • Build community with shared future, create better world • Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges • SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote • ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B • Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference • SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI

Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifi

AMSTERDAM , February 01 /Businesswire/ - Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to support its therapeutic program for the treatment of Niemann-Pick Type C (NPC) disease, which is a severe, progressive and lethal neurological disorder. The goal of the collaboration is to obtain clinical insights into genes that can reduce the severity of NPC. Under the terms of the CRADA, NICHD will grant Scenic Biotech access to its extensive clinical dataset and whole genome DNA sequence data derived from NPC patients. Forbes D. Porter, MD, PhD, Senior Investigator at NICHD, will be the principal investigator for this study based on his long-running clinical protocols that track the natural history of rare genetic disorders, including NPC.

“The CRADA with the NIH will help advance our work toward identifying genetic modifiers for NPC. Our aim is to develop novel therapeutics that act by suppressing or completely blocking the effect of a disease-causing mutated gene. Through the combined efforts with Dr. Porter’s team, we hope to further enable the discovery of a tailor-made, disease-modifying small molecule therapeutic for this devastating disease,” commented Sebastian Nijman, CSO and co-founder of Scenic Biotech.

About Scenic Biotech

Scenic Biotech is at the forefront of identifying genetic modifiers, naturally occurring genes that compensate for mutations responsible for severe diseases. Our robust technologies, reproducible approach and high-resolution insights into disease pathways enable us to develop small-molecule compounds that start with genetic modifiers to provide new therapeutic concepts. By understanding the genome’s power to correct toward health, Scenic Biotech will bring novel therapeutics to patients in need.